Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion

Lee, Seung Hyeun; Park, Myung Jae; Choi, Sue In; Lee, Sang Yeub; In, Kwang Ho

doi:10.1097/md.0000000000005975

Cited by 11 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, we did not evaluate or compare the clinical utility of other biomarkers. As previous studies have suggested,29,30 a comparison with diagnostic value or an investigation of the combined effect with established biomarkers or serum ROMO1 would provide more informative data.…”

Section: Discussionmentioning

confidence: 98%

<p>Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study</p>

Kong

Sung

Lee

2019

OTT

Self Cite

View full text Add to dashboard Cite

PurposeReactive oxygen species modulator 1 (ROMO1) is a novel protein regulating intracellular reactive oxygen species production. Although increased ROMO1 expression has been associated with poor clinical outcomes in several human malignancies, the clinical implication of this protein in a radiotherapy setting has never been explored. The aim of this study was to investigate whether ROMO1 expression is associated with survival in lung cancer patients who received radiotherapy.MethodsROMO1 protein expression was evaluated immunohistochemically using histologic score (H-score) in 49 tumor tissues from stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy. We performed survival analyses according to various clinicopathological parameters including ROMO1 expression.ResultsROMO1 expression was not associated with any clinicopathological parameter of age, sex, smoking status, stage, or histological subtype. Multivariate analyses showed that high ROMO1 expression was independently associated with worse progression-free survival (hazard ratio [HR] = 1.87, 95% confidence interval [CI]: 1.02–4.23) and with worse overall survival (HR = 2.79, 95% CI:1.13–6.87). In addition, high ROMO1 expression was independently associated with shorter time to loco-regional recurrence (HR=2.71, 95% CI:1.04–6.28) but was not associated with time to distant metastasis.ConclusionROMO1 overexpression was associated with early loco-regional recurrence and poor survival outcomes in stage III NSCLC treated with definitive radiotherapy. Our exploratory results provide a basis for further large-scale studies to validate whether ROMO1 could be a prognostic marker in this setting.

show abstract

Section: Discussionmentioning

confidence: 98%

<p>Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study</p>

Kong

Sung

Lee

2019

OTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…The diagnostic use of biomarkers for MPE is based on discriminating lung cancer from BPE with considerable sensitivity and specificity. Previous studies have already investigated the clinical value of several biomarkers in pleural fluid including (CEA), CYFRA21-1, CA125 and Romo1 [ 16 – 18 ]. Among those, CEA, CYFRA21-1 and CA125 were widely accepted in clinical performance as to distinguishing MPE from BPE.…”

Section: Discussionmentioning

confidence: 99%

Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion

Shan

Ding

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Over-expressed meningioma-associate protein (MAC30) in tissues was associated with malignant tumor differentiation, metastasis and poor prognosis. However, the attention of MAC30 in pleural effusion from lung tumor is insufficient. Our retrospective study was prepared to explore the clinical values on diagnosis and prognosis of MAC30 from malignant pleural effusion (MPE) in non-small cell lung cancer (NSCLC). Levels of MAC30 were confirmed in MPE from 48 NSCLC patients and in benign pleural effusion (BPE) from 45 controls via enzyme-linked immunosorbent assay (ELISA). The association of MAC30 in MPE with clinical significance was further determined. We found that the levels of MAC30 in MPE were obviously higher than those in BPE (p < 0.05). Moreover, with a cutoff point (17.5 ng/ml), we confirmed the sensitivity and specificity of MAC30 for MPE were 82.7% and 85.3% using ROC curve analysis. Indeed, longer overall survival (OS) was present in NSCLC patients with low MAC30 expression in MPE. Multivariate analysis explicated that elevated MAC30 in MPE was an independent prognostic factor for shorter OS of NSCLC. Our data suggests that MAC30 in pleural effusion could be a potential prognostic marker in NSCLC with MPE.

show abstract

“…Using blood and PE markers is useful for distinguishing TPEs from AD-MPEs, such as adenosine deaminase and carcinoembryonic antigen [13,14]. A number of markers can be used to predict TPEs and AD-MPEs, although their use of markers is considerably less speci c than histology.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of four coagulation function indicators for distinguishing between tuberculous pleural effusions and malignant pleural effusions due to lung adenocarcinoma

Li¹,

Gao²,

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Coagulation function indicators are often used to evaluate patients’ coagulation function.They are rarely used in disease diagnosis;their use is limited to somecoagulopathies. We described the pattern of coagulation function indicators in patients with pleural effusions and determined the diagnostic value of different abnormal patterns of these indicators for distinguishing tuberculous pleural effusions (TPEs) from malignant pleural effusions associated with lung adenocarcinoma (AD-MPEs).Methods: Patients with AD-MPEs or TPEs participated in this retrospective study.Coagulation functionindicators, including activated partial thromboplastin time, prothrombin time (PT), fibrinogen (FIB), thrombin time, fibrinogen degradation products (FDP), and D-dimer(D-D), were measured; their levels and abnormal patterns were analyzed separately and in combination,to determine the diagnostic performance of individual and combined values and the optimal diagnostic model.Results: One hundred patients with AD-MPEs and 84 patients with TPEs participated.PT, FIB, FDP, and D-Dlevels in patients with TPE were significantly higher than those in patients with AD-MPE (all P<0.01).Receiver operating characteristiccurves revealed that PT, FIB, FDP, and D-Dvalues, particularly FDP and D-D, could distinguish betweenAD-MPE and TPE. The diagnostic performance was better for the combination of the four indicators than for any single indicator (Youden’s index: 0.513; area under the curve: 0.810).The proportion of patients with abnormal patterns of all four indicators was significantly higher in those with TPE than in those with AD-MPE (P<0.001).Conclusions: Thecombined values of PT, FIB, FDP, and D-Dhave diagnostic value for distinguishing TPE from AD-MPE.

show abstract

Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion

Cited by 11 publications

References 19 publications

<p>Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study</p>

<p>Reactive Oxygen Species Modulator 1 As An Adverse Prognostic Marker In Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy: A Retrospective Pilot Study</p>

Pleural MAC30 as a prognostic marker in NSCLC with malignant pleural effusion

Diagnostic value of four coagulation function indicators for distinguishing between tuberculous pleural effusions and malignant pleural effusions due to lung adenocarcinoma

Contact Info

Product

Resources

About